Best response to first- and second-line treatment regimens given after CAR-T failure. Regimens are listed in order of descending response. To right of each regimen in the ORR% (CR%). Lenalidomide-based regimens were analyzed separately from tafasitamab + lenalidomide. Lenalidomide-based regimens included either lenalidomide alone (6) or lenalidomide plus the following: rituximab (6), rituximab + radiation (1), rituximab + steroids (1), rituximab + intrathecal chemotherapy (1), intrathecal chemotherapy (1), steroids (1), venetoclax (1), obinutuzumab (2), and obinutuzumab + venetoclax (4) (supplemental Table 6). Ab, antibody; BR, bendamustine + rituximab; No., number; n, number; PR, partial response.